Get notified when CHRS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Loan and Security Agreement With Innovatus Life Sciences Lending Fund I, LP (new) — The company's debt covenants require maintaining certain cash levels, which could restrict operational flexibility and require waivers.
Coherus Oncology launches at-the-market offering of up to $50 million in common stock
Filed August 28, 2026 · ~1 min read
Key Changes
-
high
Coherus Oncology is offering common stock with an aggregate offering price of up to $50 million in an at-the-market offering.
The Offering verify on EDGAR → -
medium
The offering is primary, with proceeds going to the company for general corporate purposes, including working capital, R&D, and commercial activities.
Use of Proceeds verify on EDGAR → -
medium
The last reported sale price was $1.46 per share on August 27, 2026, but shares will be sold at prevailing market prices over time.
The Offering verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TLRY 10-Q) is open in full — no account needed.
Partner
Trade CHRS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify